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n NIH3T3 cells, 0.001 nM of the synthetic androgen
R1881 induces and stimulates association of androgen
receptor (AR) with Src and phosphatidylinositol 3-kinase
(Pl3-kinase), respectively, thereby triggering S-phase entry.
10 nM R1881 stimulates Rac activity and membrane rufﬂing
in the absence of the receptor–Src–PI3-kinase complex
assembly. The antiandrogen Casodex and speciﬁc inhibitors
of Src and PI3-kinase prevent both hormonal effects, DNA
synthesis and cytoskeletal changes. Neither low nor high
R1881 concentration allows receptor nuclear translocation
and receptor-dependent transcriptional activity in ﬁbro-
blasts, although they harbor the classical murine AR. The
very low amount of AR in NIH3T3 cells (7% of that present
in LNCaP cells) activates the signaling pathways, but appar-
I
 
ently is not sufﬁcient to stimulate gene transcription. This
view is supported by the appearance of receptor nuclear
translocation as well as receptor-mediated transcriptional
activity after overexpression of AR in ﬁbroblasts. In addition,
AR-negative Cos cells transiently transfected with a very
low amount of hAR cDNA respond to low and high R1881
concentrations with signaling activation. Interestingly, they
do not show signiﬁcant transcriptional activation under
the same experimental conditions. Fibroblasts are the ﬁrst
example of cells that respond to steroid hormones with activa-
tion of signaling pathways in the absence of endogenous
receptor transcriptional activity. The data reported also
show that hormone concentration can be crucial in deter-
mining the type of cell responsiveness.
 
Introduction
 
Mesenchyme plays a crucial role in neoplasia. Nontumorigenic
NIH3T3 mouse embryo fibroblasts induce human prostatic
PC-3 tumor growth (Camps et al., 1990). Recombination of
prostatic epithelial cells and stromal components shows that
tumor stroma induces tumor phenotype in epithelial cells
(Olumi et al., 1999; Hayward et al., 2001). These findings
support the view that the stroma is an integral part of tumors,
and can exert a dominant force over the malignant pheno-
type under certain conditions (Matrisian et al., 2001). In
addition, androgens initially act on mesenchymal cells during
prostate development (Cunha et al., 1997); therefore, mes-
enchymal components are increasingly the focus of cancer
progression studies.
The synthetic androgen R1881 immediately triggers a direct
association of androgen receptor (AR)* and estrogen receptor
with Src in LNCaP cells, which are derived from human
prostate cancer. As a result, estradiol induces association of
the same ternary complex (Migliaccio et al., 2000). This
complex is required for powerful activation of the Src–Ras–
extracellular signal–regulated kinase (ERK) pathway by either
androgens or estradiol and subsequent DNA synthesis
(Migliaccio et al., 2000). Here, we show that a very low con-
centration of R1881 stimulates the S-phase entry of NIH3T3
cells, whereas a high hormone concentration, which maximally
stimulates DNA synthesis of LNCaP cells (Migliaccio et al.,
2000), has a negligible effect.
Cell migration is an essential process during development
and wound healing. Furthermore, the signaling pathway aber-
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rations involved in the regulation of cell migration, cell–cell
and cell–matrix interactions contribute to tumor invasion
and metastasis. The Rho-like GTPases, including Cdc42,
Rac1, and RhoA, are key regulators of signal transducing
pathways that mediate the distinct cytoskeleton changes re-
quired for cell migration (Hall, 1998). We found that, in
contrast to DNA synthesis, stimulation of NIH3T3 fibro-
blasts with high concentrations of R1881 induces rapid
membrane ruffling formation. Interestingly, rapid and tran-
sient activation of Rac precedes membrane ruffling. In a pre-
vious paper, we observed that estradiol stimulation of MCF-7
cells triggers association of its receptor with Src and p85,
which is the regulatory subunit of PI3-kinase. These two sig-
naling effectors are both required for the hormone-induced
G1-S progression (Castoria et al., 2001). Association of AR
with Src and p85 has been analyzed at low and high andro-
gen concentrations along with the role of they play in the
NIH3T3 cells responsiveness to R1881.
In the absence of hormones AR is predominantly localized
in the cytoplasm of target cells and ligand promotes its nu-
clear import (Zhou et al., 1994). In fibroblasts, the analysis
of AR localization shows that it does not enter nuclei upon
agonist stimulation. The very low levels of AR seem to be re-
sponsible for AR distribution as well as its inability to activate
gene transcription in response to hormone treatment.
 
Results
 
Low androgen concentrations induce S-phase entry of 
quiescent NIH3T3 cells
 
Fibroblasts were made quiescent using 0.5% charcoal-treated
serum and medium lacking phenol red, which has weak es-
trogen activity, for 18 h. Thereafter, 0.001 nM R1881 was
added to the medium and a 48-h time course of BrdU incor-
poration was monitored. After in vivo labeling, cells were an-
alyzed for S-phase entry by in situ immunofluorescence. Af-
ter hormone addition to the medium, a large number of cells
incorporated BrdU into DNA with a peak at 18 h (Fig. 1 A).
Next, we examined the effect of two diverse concentrations
of sex steroid hormones on BrdU incorporation of quiescent
NIH3T3 cells (Fig. 1 B). BrdU-incorporating cells increased
from 10 to 60% after 0.001 nM R1881 was added to the me-
dium. In contrast, stimulation was weak after the addition of
10 nM R1881. No increase of the S-phase entry was induced
by either 0.001 or 10 nM (the latter concentration is not de-
picted) estradiol or progestin R5020. An excess of the antian-
drogen Casodex abolished the BrdU incorporation induced
by the lower concentration of R1881, which implies that the
androgen stimulatory effect is mediated by its receptor.
We analyzed the expression of sex steroid receptors in
NIH3T3 cells using Western blot. The anti-AR antibodies
(N-20 or C-19, directed at NH
 
2
 
- and COOH-terminal se-
quences, respectively) reacted with a 108-kD band in LN-
CaP cell lysates (Fig. 1 C). Such a migration of the AR from
LNCaP cells has been previously reported (Warriar et al.,
1994). Parallel analysis in NIH3T3 cell lysate revealed a ma-
jor band migrating with an apparent molecular mass of 110
kD. The same migration was reported for the mouse AR
from different tissues (Zhou et al., 2002). A minor band mi-
grating at 95 kD was also recognized by the C-19 Ab. It
might represent an AR-truncated isoform (Wilson and
McPhaul, 1994) or a proteolytic product. Noteworthy, post-
translational modifications of AR have been described previ-
ously (Kuiper et al., 1992). Androgen receptor in fibroblasts
was only 7% of that in LNCaP cells (Fig. 1). Similarly, low
AR levels were detected with Western blot analysis of lysates
from either Src-, Ras-, or Myc-transformed NIH3T3 fibro-
blasts, as well as Swiss3T3 fibroblasts (unpublished data). In
agreement with the finding that estradiol or progestin did
not affect S-phase entry, neither estradiol receptor (ER
 
 
 
 or
Figure 1. A low androgen concentration 
specifically stimulates the S-phase entry of 
NIH3T3 cells. (A) Quiescent fibroblasts on 
coverslips were left untreated ( ) or treated ( ) 
for the indicated times with 0.001 nM R1881. 
After in vivo labeling with 100  M BrdU, the 
cells were fixed, permeabilized, and stained for 
BrdU incorporation. DNA synthesis was calculated 
by the formula: percentage of BrdU-positive cells   
(number of BrdU-positive cells/number of total 
cells)   100. (B) The cells were left untreated or 
treated with the indicated compounds, labeled 
with BrdU, and were fixed and stained after 
18 h. DNA synthesis was calculated as in A. 
Different experiments were performed and multiple 
coverslips were analyzed. The means and SEM 
are shown. (C) Lysates from quiescent NIH3T3, 
LNCaP, MCF-7, and T47D cells were immunoblotted 
with the antibodies against the indicated receptors. 
Endogenous AR in NIH3T3 cells was revealed by 
two different antibodies (either C-19 or N-20). 
The optical density/mm
2 measured by densitometric 
analysis of blot with C-19 anti-AR antibody was 
6.12 and 0.47 for AR expressed in LNCaP and 
NIH3T3 cells, respectively. In the lowest section of C, lysates from primary fibroblasts (mouse fibroblasts, MF, or mouse embryo fibroblasts, 
MEF, both at second passage) were immunoblotted with the C-19 anti-AR antibody.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
 Androgen-activated nongenomic actions |
 
 Castoria et al. 549
 
ER
 
 
 
) nor progesterone receptor (PgR-B or -A) was detected
in NIH3T3 cell lysates (Fig. 1 C). As a positive control, we
used ER
 
 
 
, ER
 
 
 
, or PgR (B and A isoforms) present in ly-
sates from MCF-7, LNCaP, and T47D cells, respectively
(Fig. 1 C). Remarkably, a 110-kD protein immunoreacting
with the C-19 anti-AR antibody was also detected by West-
ern blot analysis of lysates from mouse female and embryo
primary fibroblasts (Fig. 1 C, lower section).
Together, Fig. 1 shows that a very low concentration of
androgen R1881 promotes the S-phase entry of NIH3T3 fi-
broblasts. This effect, which is substantially reduced by the
antiandrogen Casodex, correlates with detection of a protein
recognized by two different anti-AR antibodies.
 
Role of the extranuclear signaling effectors in 
androgen-stimulated S-phase entry of NIH3T3 cells
 
Next, we studied the regulation of androgen-induced S-phase
entry in response to the expression of various extranuclear ef-
fectors. In NIH3T3 cells, we transiently transfected the
following: the catalytically inactive form of Src (Lys295
changed to methionine; Src K
 
 
 
; Barone and Courtneidge,
1995), the kinase-dead MAPK/ERK kinase-1 (MEK-1;
Ser221 changed to alanine; A221–MEK-1, Cowley et al.,
1994), the dominant-negative regulatory subunit of PI3-
kinase (
 
 
 
p85
 
 
 
; Dhand et al., 1994), or the Myc-tagged kinase-
dead Akt (Lys 179 changed to methionine; Akt K
 
 
 
; Kohn et
al., 1996). 12 h after transfection, cells were made quiescent
Figure 2. Requirement for the Src–ERK and PI3-kinase–
Akt pathways in the androgen-stimulated S-phase entry 
is correlated to AR–Src–PI3-kinase association in 
NIH3T3 cells. Fibroblasts on coverslips were either 
untransfected or transfected with the plasmids expressing 
the indicated proteins. (A) Transfected cells were made quiescent, and then left unstimulated or stimulated with 0.001 nM R1881. BrdU was 
added and coverslips were analyzed for BrdU incorporation. In transfected cells, BrdU incorporation was calculated by the formula: percentage 
of BrdU-positive cells   (number of transfected BrdU-positive cells/number of transfected cells)   100 and compared with BrdU incorporation 
of untransfected cells from the same coverslips. For each plasmid, data are derived from at least 200 scored cells. The results of more than 
two independent experiments have been averaged; means and SEM are shown. The statistical significance of these results was also evaluated 
by paired t test. P values were  0.001 for cells transfected with either Src K
 ,  p85 , Akt K
 , or A221–MEK-1. The difference in BrdU 
incorporation between the cells transfected with Src K
  and those transfected with Src wt was significant (P   0.005). Also significant 
(P   0.001) was the difference in BrdU incorporation between the cells transfected with  p85  and those transfected with p85  wt. 
No significance was attributed to the difference in BrdU incorporation between the cells transfected with either Src wt or p85  wt and 
nontransfected cells stimulated with the androgen R1881. (B) Representative images of one of the experiments in A. Fluorescence in the left 
panels is from reactivity with either the anti-Src mAb (top) or the anti–MEK-1 Ab (bottom). Arrows and arrowheads mark the cells transfected 
with either Src K
  or A221–MEK-1 expressing plasmids. The central panels show staining with anti-BrdU antibody. Hoechst 33258 nuclear 
staining is presented in the right panels. Quiescent NIH3T3 cells were either left untreated or treated for 2 min with the indicated compounds. 
(C) Lysate proteins were immunoprecipitated with either control antibody (ctrl) or the 327 anti-Src monoclonal antibody (anti-Src mAb). (D) Lysate 
proteins were immunoprecipitated with either control antibody (ctrl) or rabbit polyclonal anti-p85 antibody (anti-p85 Ab). (C and D) Immuno-
complexes were analyzed by immunoblot with antibodies against the indicated proteins. (D) By an NIH 1.61 image program, a 38% increase 
of AR/p85 association was detected on 0.001 nM R1881 stimulation of cells. This experiment was reproduced with similar findings. (E) Lysate 
proteins from NIH3T3 cells challenged for 2 min with the indicated compounds were immunoblotted with the C-19 anti-AR antibody.T
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and left unstimulated or stimulated with 0.001 nM R1881
for an additional 18 h. After in vivo labeling with BrdU, the
cells on coverslips were fixed and stained. Several indepen-
dent transfections were performed and multiple coverslips
were analyzed. The number of BrdU-positive cells expressing
either Src K
 
 
 
, A221–MEK-1, 
 
 
 
p85
 
 
 
, or the Myc-tagged
Akt K
 
 
 
 was compared with the number of BrdU-positive
nontransfected cells. Data from different experiments were
pooled and statistically analyzed (Fig. 2 A). About 10% of
nontransfected cells incorporated BrdU in the absence of
R1881. Addition of the hormone to the medium increased
the number of BrdU-positive cells to 
 
 
 
60%. Overexpression
of Src K
 
 
 
, A221–MEK-1, 
 
 
 
p85
 
 
 
, or the Myc-tagged Akt
K
 
 
 
 inhibited the androgen-stimulated S-phase entry by 75,
67, 59, and 68%, respectively. In contrast, overexpression of
the wild-type form of Src (Src wt) or the wild-type form of
p85
 
 
 
 (p85
 
 
 
 wt) did not affect the androgen-induced S-phase
entry. Transfection of NIH3T3 fibroblasts with the pSG5
empty plasmid did not modify BrdU incorporation irrespec-
tive of the presence or absence of R1881 (unpublished data).
Images from one representative experiment with Src K
 
 
 
 and
A221–MEK-1 are presented. The left-hand panels of Fig. 2
B show cells expressing Src K
 
 
 
 (top) or A221–MEK-1 (bot-
tom). The same cells did not incorporate BrdU when visual-
ized with anti-BrdU antibody (Fig. 2 B, middle). The nuclear
staining with Hoechst is also shown (Fig. 2 B, right).
To investigate further the role of Src and PI3-kinase in an-
drogen-induced S-phase entry, we challenged NIH3T3 cells
with 0.001 or 10 nM R1881 and immunoprecipitated the ly-
sates with anti-Src (Fig. 2 C) or anti-p85 antibodies (Fig. 2
D). In Fig. 2 C, immunocomplexes were blotted with either
anti-Src (top) or anti-AR antibodies (bottom). At the lower
R1881 concentration, but not at a 1,000-fold excess of the an-
tiandrogen Casodex, Src coimmunoprecipitated with the two
proteins immunodetected by the C-19 anti-AR antibody in
NIH3T3 cell lysates that migrated at 110 and 95 kD. Re-
markably, no association of Src with AR occurred at the
higher R1881 concentration. Fig. 2 D shows immunocom-
plexes blotted with anti-p85 (top) or anti-AR antibodies (bot-
tom). In unchallenged cell lysates, p85 coimmunoprecipitated
with the 110-kD AR. Stimulation with the lower R1881 con-
centration, slightly (40%) increased this coimmunoprecipita-
tion, which was undetectable at a higher concentration of
R1881 (Fig. 2). The control antibody (ctrl) did not precipi-
tate Src (Fig. 2 C) or p85 (Fig. 2 D). The possibility that
treatment of cells could modify the AR level was excluded by
the finding that the same amount of AR was detected by im-
munoblot of lysates, irrespective of R1881 and Casodex con-
centrations used to stimulate NIH3T3 cells (Fig. 2 E).
These data demonstrate that, in contrast to the higher
R1881 concentration, the lower concentration induces coim-
munoprecipitation of Src with AR and increases AR–PI3-kinase
coimmunoprecipitation. Such a coimmunoprecipitation is as-
sociated with the androgen stimulated S-phase entry.
 
Androgen at high concentration induces Rac activation 
and membrane ruffling in NIH3T3 fibroblasts
 
NIH3T3 cells on coverslips were serum-starved and main-
tained in DME lacking phenol red. In a preliminary experi-
ment (unpublished data), the cells were challenged with
0.001 or 10 nM R1881 for various times and stained with
Texas red–phalloidin to visualize F-actin. Treatment of cells
with 10 nM R1881 caused membrane ruffling, which ap-
peared as early as 10 min after stimulation and increased af-
ter 20 min. In contrast, there was no response to treatment
with 0.001 nM R1881, even after 40 min of ligand stimula-
tion. In Fig. 3 (A–C) representative images of one experi-
ment are shown. R1881 induced pronounced membrane
ruffling at 10 nM, whereas it was ineffective at 0.001 nM. In
addition, the pure antiandrogen Casodex prevented the ef-
fect of 10 nM androgen (Fig. 3 D). Next, the effect of sig-
naling inhibitors was evaluated. Both the Src inhibitor, PP2
(Fig. 3 E), and the PI3-kinase inhibitor, LY294002 (Fig. 3
F), prevented cytoskeletal response to the androgen. In addi-
tion, PP2 affected cell morphology, resulting in a more
roundish phenotype.
Because Rac activation is implicated in membrane ruffling
and lamellipodia formation (Ridley, 2001), we next evalu-
ated the effect of androgen on Rac activity using a pull-
down assay. Stimulation of serum-starved NIH3T3 cells
with 10 nM androgen induced a rapid and transient activa-
tion of Rac, with a peak at 2 min (Fig. 4 A). Interestingly,
Figure 3. A high androgen concentration induces membrane 
ruffling mediated by PI3-kinase and Src. Serum-starved NIH3T3 
cells on coverslips were left untreated or treated for 20 min with the 
indicated compounds. The chemical inhibitors PP2 and LY294002 
(Qbiogene) at 5 and 10  M, respectively, were added 10 min before 
the hormonal stimulation. A 1,000-fold excess of Casodex was 
added 5 min before the hormonal stimulation. Cells stained with 
Texas red–phalloidin were visualized by a fluorescent microscope. 
Micrographs are representative of three independent experiments.T
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the lower androgen concentration (0.001 nM R1881) did
not affect Rac activation. Consistent with the data on the
androgen-induced membrane ruffling, LY294002 and PP2
inhibited the androgen-induced Rac1 activation (Fig. 4 B).
Activation of signaling pathway(s) is involved in the estra-
diol-induced cytoskeleton changes in endothelial cells (Ra-
zandi et al., 2000) and implicated in morphological changes
induced by estradiol in breast cancer–derived cells (Song et
al., 2002). Here, we demonstrate that there is a hormone-
regulated correlation between cytoskeletal changes and Rac
activation; thus, Rac represents a new signaling effector acti-
vated by steroid hormones.
 
Protein interacting with anti-AR antibodies does not 
translocate into the nuclei of NIH3T3 fibroblasts
 
We used in situ immunofluorescence to determine the intra-
cellular localization of protein interacting with either the
C-19 or the N-20 anti-AR antibodies. Quiescent NIH3T3
and LNCaP cells were unstimulated or stimulated with 10
nM R1881 for 30 min and stained for AR detection. Inter-
estingly, whatever the antibody used (either C-19 or N20),
fluorescence was observed in the cytoplasm of NIH3T3 cells
(Fig. 5, A–B
 
1
 
). Similar results (unpublished data) were ob-
tained irrespective of signal duration (60 and 120 min) and
ligand concentration (0.001 nM). Conversely, stimulation
of human prostate carcinoma LNCaP cells induced nuclear
import of AR in 
 
 
 
40% of cells as observed by staining with
the C-19 anti-AR antibody (Fig. 5, C and C
 
1
 
). Specificity of
the C-19 staining in NIH3T3 cells was confirmed by the al-
most complete displacement of immunofluorescence ob-
served with an excess of peptide against which the C-19 an-
tibody is raised (Fig. 5, D and D
 
1
 
).
 
Lack of androgen-stimulated transcription activity in 
NIH3T3 cells
 
The prevalently extranuclear localization of AR prompted us
to analyze the effect of androgen on the reporter gene tran-
scription. Two androgen enhancers, the 3416 and 3424
constructs (Verrijdt et al., 2000), were transiently trans-
Figure 4. PI3-kinase and Src mediate Rac activation induced by 
high androgen concentration. (A) Serum-starved NIH3T3 cells were 
left untreated or treated for the indicated times with either 0.001 or 
10 nM R1881. (B) The cells were left untreated or treated for 2 min 
with 10 nM R1881 in the absence or presence of PP2 or LY294002 
(at 5 and 10 mM, respectively). The chemical inhibitors were added 
10 min before the hormonal stimulation. Lysate proteins were 
submitted to a Rac pull-down assay, and the eluted proteins were 
immunoblotted with the anti-Rac antibody.
Figure 5. Immunostaining of AR in NIH3T3 and LNCaP cells. Quiescent NIH3T3 and LNCaP cells on coverslips were untreated or treated 
for 30 min with 10 nM R1881. Cells were permeabilized as described in Materials and methods, and AR was visualized by immunofluorescence 
using the indicated antibodies. (A–B1) Regardless of the antibody used (either C-19 or N-20), AR is localized in the extranuclear compartment 
of untreated (A and B) or androgen-treated NIH3T3 cells (A1 and B1). Exposure time in NIH3T3 cells was enhanced to better visualize cytoplasm 
AR. (C and C1) AR is localized in both the nuclear and extranuclear compartment of untreated LNCaP cells (C). 10 nM R1881 induced 
nuclear import of AR in LNCaP cells (C1). The cells that fall into the category of predominantly nuclear staining are marked with arrows. 
Immunostaining of AR from at least 200 scored LNCaP cells was also monitored, and the data were expressed as a percentage of cells that fall 
into the category of predominantly nuclear staining. In LNCaP cells, this value was  20% and shifted to  65% when they were stimulated 
for 30 min with 10 nM R1881. (D and D1) Quiescent NIH3T3 cells on coverslips were fixed and permeabilized as described in Materials and 
methods. AR was visualized by immunofluorescence using the C-19 anti-AR antibody alone (D) or in the presence (D1) of a 100-fold excess 
of a competing peptide (AR/C-19 P; Santa Cruz Biotechnology, Inc.).T
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fected in NIH3T3 cells and the effect exerted by androgen
on the reporter gene transcription was evaluated after 18 h
of cell treatment with either 0.001 or 10 nM R1881. In
agreement with the extranuclear localization of AR, neither
high nor low androgen concentrations increased luciferase
activity (Fig. 6, A and B). 
It is unlikely that these findings depend on the cell milieu
because a substantial increase of luciferase activity (39- and
48-fold for the 3424 or the 3416 construct, respectively) was
observed on 10 nM androgen stimulation of NIH3T3 cells
overexpressing hAR (Fig. 6, A and B). Such overexpression
is confirmed by Western blot analysis of lysates from
NIH3T3 cells transfected with hAR cDNA in the presence
of either 3416 or 3424 construct (Fig. 6 C). In addition, the
cell environment does not interfere with AR nuclear translo-
cation because the overexpressed hAR enters nuclei on a 10-
nM ligand stimulation (Fig. 6 D
 
2
 
). Interestingly, neither
gene transcription (Fig. 6, A and B) nor nuclear import (Fig.
6 D
 
1
 
) occurred after stimulation of transfected NIH3T3
cells with 0.001 nM R1881, implicating that both processes
occur at high levels of both, receptor and ligand.
Results illustrated in Figs. 5 and 6 demonstrate that en-
dogenous AR does not enter nuclei of NIH3T3 cells and,
consequently, it is unable to activate gene transcription.
Nevertheless, it does induce S-phase entry and membrane
ruffling on androgen stimulation of the cells.
 
Identification of murine AR in NIH3T3 fibroblasts 
by RT-PCR
 
Data in the previous sections led us to further identify the
AR expressed in NIH3T3 cells. We generated cDNA from
poly(A)
 
 
 
 RNA of growing cells by reverse transcriptase. The
cDNA was amplified by PCR using primers for the NH
 
2
 
terminus, the DNA-binding domain, and the ligand-bind-
ing domain (LBD) of AR. The analysis by agarose gel of
PCR products (Fig. 7) revealed DNA bands of the expected
size of 1,300, 850, and 420 bp for the NH
 
2
 
 terminus, the
DNA-binding domain, and the LBD (Fig. 7, A–C, left
lanes) of AR, respectively. The corresponding PCR products
from the AR of LNCaP cells were analyzed in parallel (Fig.
7, A–C, right lanes). DNA sequencing (unpublished data)
confirmed that the PCR fragments from NIH3T3 cells con-
tained the predicted sequence of AR NH
 
2
 
 terminus, DNA
binding, and LBD, thereby proving that NIH3T3 cells con-
tain the classical mouse AR.
 
Low AR expression mediates signaling activation but 
not gene transcription in Cos cells
 
Our results indicate that AR expressed in NIH3T3 cells is
transcriptionally inactive while it efficiently stimulates the
cytosolic-coupled pathways. To verify whether the low
amount of endogenous AR might be responsible for this be-
havior, we transiently transfected AR-negative Cos cells with
two different amounts of hAR cDNA (either 500 or 1 ng)
and analyzed the AR expression levels (Fig. 8 A, inset). The
ability of AR to transactivate the androgen-responsive ele-
ment (ARE) 3416 reporter gene was then assayed. Irrespec-
Figure 6. Androgen-stimulated gene transcription in NIH3T3 
cells before and after overexpression of hAR and hAR intracellular 
localization. NIH3T3 cells were transfected with either ARE 3424 
(A) or 3416 (B) constructs with or without hAR-expressing plasmid. 
Cells were left unstimulated or stimulated for 18 h with the indicated 
concentrations of the androgen R1881. The luciferase activity was 
assayed, normalized using  -gal as an internal control, and expressed 
as fold induction. The same lysates were used for Western blot 
analysis with C-19 anti-AR Ab (C). (D and D2) NIH3T3 cells were 
transfected with hAR-expressing plasmid, and then made quiescent. 
Cells were left unstimulated (D) or stimulated for 1 h with either 
0.001 nM (D1) or 10 nM R1881 (D2). Fixed cells on coverslips were 
permeabilized as described in Materials and methods, and hAR 
was visualized by immunofluorescence using the rabbit polyclonal 
anti-AR (N-20) antibody.
Figure 7. Molecular analysis of AR-RNA expressed in NIH3T3 
and LNCaP cells. Total RNA and poly(A)
  RNA was obtained from 
growing LNCaP or NIH3T3 cells, respectively. cDNA was synthesized 
and amplified by PRC using specific primers for the NH2 terminus 
(A), DNA binding (B), and LBD (C) of mouse AR. The PCR products 
were submitted to agarose gel. PCR products generated without 
reverse transcriptase from poly(A)
  RNA of NIH3T3 cells were 
submitted to the same analysis, as a control (ctrl).T
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tive of the amount of expressed hAR, no transcription stim-
ulation occurred on treatment of Cos cells with 0.001 nM
R1881 (Fig. 8 A). When the same cells were stimulated with
10 nM R1881, those expressing the lowest amount of hAR
showed a negligible increase of the transcriptional activity
(4% of that detected in cells showing the highest amount of
hAR; Fig. 8 A). In sharp contrast, Cos cells expressing the
lowest amount of AR showed a strong Src activity increase
after stimulation with 0.001 nM R1881. Such an increase
was comparable with that observed in cells expressing high
levels of AR when stimulated by 10 nM R1881 (Fig. 8 B).
Noteworthy, like in NIH3T3 cells overexpressing hAR, in
Cos cells stimulation of AR-dependent transcription requires
high levels of both ligand and AR. Altogether, these data sup-
port the hypothesis that the very low AR amounts expressed
in NIH3T3 cells are sufficient to activate cytoplasmic func-
tions but inadequate to stimulate gene transcription.
 
Discussion
 
The expression and activity of steroid receptors is not re-
stricted to epithelial cells. Mesenchyme AR is required to
initiate prostatic bud formation (Cunha et al., 1987). Estro-
gen receptor-
 
 
 
 is present in the breast stroma of rodents and
is responsible for secretion of growth factors (epithelial cellu-
lar mitogens) in response to estradiol. Tissue recombinants
with stroma and epithelium from normal as compared with
ER
 
 
 
 knockout mice showed that stromal ER
 
 
 
 is responsible
for estrogen-induced epithelial growth (Cunha et al., 1997).
Moreover, the stroma of human mammary cancers contains
ER
 
 
 
 (Jensen et al., 2001).
Androgen activates different signaling effectors in such
cell types as prostate stromal cells, LNCaP cells, and osteo-
blasts (Peterziel et al., 1999; Migliaccio et al., 2000; Kous-
teni et al., 2001). We previously described signaling path-
way activation and consequent DNA synthesis in various
epithelial cells stimulated by the sex steroid hormones (Di
Domenico et al., 1996; Migliaccio et al., 1996, 1998, 2000;
Castoria et al., 1999, 2001). We now report that androgen
stimulation of NIH3T3 cells induces them to synthesize
DNA. This effect is androgen-specific. It correlates with the
presence of a 110-kD protein interacting with two different
anti-AR antibodies in NIH3T3 cells and is prevented by Ca-
sodex, a specific AR antagonist. Interestingly, a similar im-
munoreactive protein is recognized by the C-19 anti-AR an-
tibody in Western blot analysis of lysates from mouse female
and embryo primary fibroblasts. This indicates that AR ex-
pression is not restricted to immortalized fibroblasts.
As in LNCaP cells (Migliaccio et al., 2000), the Src–ERK
pathway is required for androgen-induced DNA synthesis be-
cause dominant-negative forms of signaling effectors prevent
this synthesis. We provide the first evidence that the PI3-
kinase–Akt pathway also mediates androgen-induced S-phase
entry. Noteworthy, estradiol activation of this pathway has
the same role in mammary cancer–derived MCF-7 cells (Cas-
toria et al., 2001). Therefore, different steroid hormones can
activate the Src- and PI3-kinase–dependent pathways in dif-
ferent cell types and, thus, exert mitogenic effects. Interest-
ingly, a very low (0.001 nM) R1881 concentration is required
for a pronounced DNA synthesis. This, together with the low
level of AR expression in fibroblasts, shows that agonist bind-
ing to a very small number of receptor molecules induces
DNA synthesis. Similar conclusions have been previously
reached for estrogen-induced proliferation in PR1 pituitary
lactotroph tumor–derived cells (Chun et al., 1998) and
low concentrations of estradiol or R1881 efficiently induce
S-phase entry of MCF-7 or LNCaP cells (unpublished data).
In addition, the androgen-induced S-phase entry of NIH3T3
fibroblasts is restricted to a single cell cycle (Fig. 1 A). Fluctu-
ation of cell cycle regulators is responsible for similar findings
in progestin-stimulated T47D cells (Horwitz et al., 1982).
In NIH3T3 cells stimulated with 0.001 nM R1881, Src
and p85 associated with AR. Interestingly, the higher R1881
concentration weakly stimulated DNA synthesis and did not
induce association of AR with Src or p85. Consequently,
this interaction appears to play a role in DNA synthesis
stimulation. We previously reported that the hAR–Src asso-
ciation is direct and requires the Src-SH3 domain and a pro-
line stretch (372–379) of the receptor (Migliaccio et al.,
2000). Therefore, it is likely that the homologous proline
stretch (367–373) present in the mouse AR is responsible
for the association of AR with Src in fibroblasts.
The outcome of signaling activation can depend on differ-
ences in ligand concentration (Marshall, 1995), and exces-
Figure 8. In Cos cells expressing very low amount of hAR, 
stimulation by 0.001 nM R1881 triggers the Src kinase activity 
but not gene transcription. Cos cells were transfected with the ARE-
3416-Luc reporter gene in the absence or presence of the indicated 
amounts of hAR cDNA. (A) Cells were left unstimulated or stimulated 
for 18 h with the indicated concentrations of the androgen R1881. 
The luciferase activity was assayed, normalized using  -gal as an 
internal control, and expressed as fold induction. The same lysates 
were used for Western blot analysis with the C-19 anti-AR Ab (A, inset). 
(B) Quiescent cells were left unstimulated or stimulated for 2 min 
with the indicated concentrations of R1881. Lysates were either 
immunoblotted with the C-19 anti-AR Ab (top) or immunoprecipitated 
with anti-Src mAb. Immunoprecipitates were either blotted with 
anti-Src mAb (middle) or assayed for Src kinase activity using 
enolase as a substrate (bottom).T
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sive signals inhibit the DNA synthesis entry of the cell cycle
in certain systems (Olson et al., 1998). Here, we show that
stimulation of NIH3T3 cells with a high (10 nM) androgen
concentration leads to rapid activation of Rac, with a maxi-
mal effect within 2 min. Rac activation rapidly causes
changes in the actin assembly that result in membrane ruf-
fling. In addition to regulating cytoskeletal changes and mo-
tility of normal and neoplastic cells, Rac can act as an onco-
gene when overexpressed in fibroblasts. Its linkage to cell
transformation occurs through the Ras and the PI3-kinase–
dependent pathways, independently of Akt (Vivanco and
Sawyers, 2002). The inhibition of androgen-stimulated Rac
by Src and PI3-kinase inhibitors observed in this paper is in
agreement with this and other papers. Class Ia PI3-kinase
can act upstream of Rac (Plattner et al., 1999; Ridley, 2001)
and Src has been implicated in PDGF-mediated membrane
ruffling of mouse embryo fibroblasts (Plattner et al., 1999).
The observation that DNA synthesis and membrane ruffling
both require Src and PI3-kinase activities indicates that the
signaling effectors mediate different effects that depend on
different ligand concentrations. The finding that androgen
concentration regulates the association between AR and sig-
naling effectors suggests that assembly or disassembly of dif-
ferent modules are involved in the different androgen effects
triggered by low and high hormone concentrations. The ob-
servation that high ligand concentration, whereas it dissoci-
ates the AR–Src–PI3-kinase complex, stimulates ruffling
through a process that still depends on Src and PI3-kinase
activities is reminiscent of the multi-adaptor Cb1 mutant ac-
tion. This mutant is unable to bind signaling molecules,
nevertheless, it strongly enhances the PDGF-induced mem-
brane ruffling through a process that requires Src and PI3-
kinase (Scaife et al., 2003). The observation that different
androgen levels trigger different responses in NIH3T3 cells
is a remarkable example of the pronounced flexibility of cell
responsiveness to steroids.
An AR nontranslocable to nuclei has been detected in T
cells (Benten et al., 1999) and a functional membrane test-
osterone receptors that modify actin cytoskeleton has been
recently identified in LNCaP cells (Kampa et al., 2002). The
experiments reported herein show that the AR present in
NIH3T3 fibroblasts does not enter the nuclei in response to
androgen, as assessed by two different anti-AR antibodies.
As a consequence, it does not activate gene transcription.
These findings reinforce the concept that commitment to
S-phase entry (Castoria et al., 1999) and induction of mem-
brane ruffling do not require transcriptional activity of ste-
roid receptors.
The expression of AR in NIH3T3 cells is very low. Nu-
clear translocation of AR and ARE-dependent transcription
are detected only after exogenous AR overexpression in the
presence of high androgen concentration. Altogether, these
findings suggest that the amount of AR in fibroblasts is suffi-
cient to engage cytosol-coupled signaling effectors but not to
trigger gene transcription. This hypothesis is supported by
the finding that AR-negative Cos cells, after expression of a
very low amount of AR, respond with Src activation on stim-
ulation with high or low androgen concentration, whereas ef-
ficient AR-dependent gene transcription requires high ligand
and AR concentration. In addition to NIH3T3 cells, other
 
mesenchymal cells contain very low amounts of steroid re-
ceptors (Manolagas and Kousteni, 2001). Like fibroblasts,
they might respond to hormones with S-phase entry, cyto-
skeletal changes, and other effects through activation of sig-
naling pathways in the absence of receptor transcriptional
activity. Fibroblasts emerge as a new model of hormone-
responsive cells that can be exploited to better understand the
early, extranuclear effects of steroid hormones.
 
Materials and methods
 
Constructs
The cDNA coding hAR was cloned into the pSG5 expression vector as re-
ported previously (Chang et al., 1988). The wild-type and dominant-nega-
tive  p85  were cloned into the pSG5 vector. The Myc-His–tagged domi-
nant-negative Akt (K179M) in pUSEAmp was purchased from UBI. cDNAs
encoding either the wild-type or kinase-inactive form of Src (Lys-259
changed to methionine) were cloned into pSG5 (Barone and Courtneidge,
1995). cDNA encoding the kinase-dead MEK-1 (Ser-221 changed to ala-
nine; A221–MEK-1) was cloned into pEXV3 (Cowley et al., 1994). The
3416 construct, containing four copies of the wild-type slp-HRE2 (5 -TGG-
TCAgccAGTTCT-3 ) and the 3424 construct (5 -TGGACAgccAGTTCT-3 ),
were cloned in the NheI site in pTK-TATA-Luc (Verrijdt et al., 2000).
Cell culture, transfection, and transactivation assay
Fast growing human prostate cancer LNCaP cells (FGC-LNCaP cells at sev-
enth passage; American Type Culture Collection), low passage mouse em-
bryo NIH3T3 fibroblasts, and Cos cells were grown as reported previously
(Migliaccio et al., 1998, 2000; Castoria et al., 1999). Mouse female as well
as embryo primary fibroblasts were grown at 37 C and 5% CO2 in DME
supplemented with 10% FBS and antibiotics. For S-phase entry analysis,
NIH3T3 cells were seeded onto gelatin-precoated coverslips at 60% conflu-
ence and made quiescent by serum starvation (Castoria et al., 1999). Cells
were stimulated with the indicated concentrations of steroids (dissolved in
0.001% ethanol, final concentration). Control cells were treated with the ve-
hicle alone. The effect of Casodex (Zeneca) on S-phase entry was monitored
using a 1,000-fold excess of the antagonist. The antiandrogen was also solu-
bilized in ethanol (0.001%, final concentration). When indicated, NIH3T3
fibroblasts were plated onto coverslips at 60% confluence in phenol red–
free DME containing 10% charcoal-stripped serum, and then transfected by
Superfect (QIAGEN) together with 2  g of either Src K
  or Src wt or A221–
MEK-1. 12 h later, transfected cells were made quiescent (Castoria et al.,
1999) and maintained in this condition for an additional 18 h. 
Transfections of NIH3T3 cells with either p85  wt,  p85 , or the Myc-
tagged Akt K
  have been described previously (Castoria et al., 2001). Fi-
broblasts were left stimulated with 0.001 nM R1881 (Zeneca) for 24 h. The
androgen was dissolved in ethanol (0.001%, final concentration), and con-
trol cells were treated with the vehicle alone. For androgen-stimulated
transcriptional analysis, NIH3T3 fibroblasts were plated at 70% confluence
in phenol red–free DME containing 10% charcoal-stripped serum. After 48 h,
the cells were transfected by Superfect with 4  g of either 3416-pTK-
TATA-Luc or 3424-pTK-TATA-Luc constructs, alone or with 1  g pSG5-
hAR–expressing plasmid. Cos cells were plated at 70% confluence in phe-
nol red–free DME containing 5% charcoal-stripped serum. After 48 h, the
cells were transfected by Superfect with 4  g 3416-pTK-TATA-Luc, alone
or with the indicated amounts of pSG5-hAR–expressing plasmid. 24 h
later, transfected cells were stimulated with the indicated concentration of
R1881 (dissolved in 0.001% ethanol, final concentration) for 18 h. Control
cells were treated with the vehicle alone. Lysates were prepared and the lu-
ciferase activity was measured using a luciferase assay system (Promega).
The results were corrected using CH110-expressed  -galactosidase activity
(Amersham Biosciences). For androgen-stimulated translocation analysis,
NIH3T3 fibroblasts were plated onto coverslips at 60% confluence in phe-
nol red–free DME containing 10% charcoal-stripped serum, and trans-
fected by Superfect with 1  g pSG5-hAR–expressing plasmid. 24 h later,
transfected cells were made quiescent, and stimulated for 1 h with the indi-
cated concentration of R1881 (dissolved in 0.001% ethanol, final concen-
tration). Control cells were treated with the vehicle alone.
RNA extraction, reverse transcription-PCR, and DNA sequencing
Total RNA was extracted from growing LNCaP cells using TRIzol reagent
(Life Technologies) according to the manufacturer’s instructions. Poly(A)
 
RNA was prepared from growing NIH3T3 fibroblasts using the OligotexT
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mRNA kit (QIAGEN). Random primed double-strand cDNA was synthe-
sized using the Superscript first-strand synthesis system for RT-PCR (Invitro-
gen). PCR was carried using Platinum Taq DNA polymerase (Invitrogen)
and the oligonucleotide primer pairs TRP 731 5 -TGGCGGTCCTTCAC-
TAATGTCAACTCCAGG-3  together with ASP 870 5 -GTCCACGCTCAC-
CATATGGACTTGATTAG-3 ; TRP 731 5 -TGGCGGTCCTTCACTAATGT-
CAACTCCAGG-3  together with 2,760 nt 5 -AGGCAGAAGACAT-
CTGGAAAGGGAACAAGGTGGG-3  for 35 cycles using the following pa-
rameters: 96 C for 30 s, 60 C for 1 min, and 72 C for 1 min. For the oligo-
nucleotide primer pairs NH1 5 -ATGGAGGTGCAGTTAGGGCTGGGA-3 
and Tyr460 5 -ATAGGGGGCTACAGGCCCGGCATCGCTTGG-3 , and
Pro 451 5 -CCAAGCGATGCCGGGCCTGTAGCCCCCTAT-3  and Arg740
5 -CCTGGAGTTGACATTAGTGAAGGACCGCCA-3 , PCR was car-
ried for 35 cycles using the following parameters: 96 C for 30 s,
64 C for 1 and 5 min, and 72 C for 2 min. The specificity of each
pair of the oligos used was verified using the BLAST Program (Sam-
brook and Russell, 2001). PCR products were eluted from agarose
gel with QIAEX II kit (QIAGEN) and sequenced with Thermo Seque-
nase radiolabeled Terminator Cycle Sequencing kit (Amersham Bio-
sciences) using either the oligos used for PCR amplification or spe-
cific internal oligos.
Immunofluorescence, DNA synthesis analysis, 
and cytoskeletal changes
LNCaP cells and NIH3T3 fibroblasts on coverslips were challenged with
the indicated concentration of R1881 in ethanol. Control cells were
treated with the vehicle alone (0.001%, final concentration). Unless other-
wise stated, cells on coverslips were washed once with PBS, fixed for 10
min with PFA (3%, wt/vol in PBS), permeabilized for 5 min with Triton
X-100 (0.2%, vol/vol in PBS), and incubated for 1 h with PBS containing 1%
vol/vol FCS. Coverslips were stained for in situ AR localization. Diluted
(1:100 in PBS containing 0.01% BSA) anti-AR (C-19; Santa Cruz Biotechnol-
ogy, Inc.) rabbit polyclonal antibody was used and the incubation was per-
formed for 1 h at room temperature. For competition experiments, diluted
(1:100 in PBS containing 20  g C-19 peptide and 0.01% BSA) anti-AR
C-19 antibody was used. After extensive washings in PBS, coverslips were
incubated for 45 min with diluted (1:200 in PBS containing 0.01% BSA)
Texas red–conjugated affinipure anti–rabbit IgG (Jackson ImmunoResearch
Laboratories). hAR overexpressed in NIH3T3 cells was visualized using di-
luted (1:100 in PBS containing 0.01% BSA) anti-AR (N-20; Santa Cruz Bio-
technology, Inc.) rabbit polyclonal antibody and the FITC-conjugated sec-
ondary antibody was used at 1:200 dilution in PBS containing 0.01% BSA.
Endogenous AR in NIH3T3 cells was also revealed using the anti-AR
(N-20; Santa Cruz Biotechnology, Inc.) rabbit polyclonal antibody. Cells on
coverslips were submitted to methanol fixation (100% methanol at  20 C)
as described (Spector et al., 1998). Coverslips were incubated for 1 h with
PBS containing 1% vol/vol FCS and mouse AR was stained using diluted
(1:50 in PBS) N-20 rabbit polyclonal antibody. The Texas red–conjugated
affinipure anti–rabbit IgG (Jackson ImmunoResearch Laboratories) was
used at 1:100 dilution in PBS. DNA synthesis was assayed by a 4-h pulse
with 100  M BrdU (Boehringer), and BrdU incorporation was monitored
as reported in Castoria et al. (1999); Src wt or Src K
  was visualized ac-
cording to the same paper. A221–MEK-1, p85  wt,  p85 , and the Myc-
His–tagged Akt K
  were visualized as described previously (Migliaccio et
al., 2000; Castoria et al., 2001). Coverslips were washed with PBS and nu-
clei stained with Hoechst 33258 (Sigma-Aldrich). To determine cytoskele-
tal changes, quiescent NIH3T3 on coverslips were maintained for 3 h in
serum-free DME and stimulated with the androgen R1881 (dissolved in
0.001% ethanol, final concentration) for the indicated times. Control cells
were treated with the vehicle alone. Cells were fixed, permeabilized,
washed, and stained with Texas red–labeled phalloidin (Sigma-Aldrich) as
reported in Barone et al. (2001). Images were generated with an Axiophot
(Carl Zeiss MicroImaging, Inc.) or a DMLB (Leica) fluorescent microscope
using 40  and 100   objectives. Images were processed using either
KS300 (Carl Zeiss MicroImaging, Inc.) or IM1000 (Leica) software.
Immunoprecipitation and Src and Rac assays
For Src activity assays, Cos cells transfected with hAR as indicated (see
Cell culture, transfection, and transactivation assay) were made quiescent
by serum starvation. The phenol red–free DME was supplemented with
0.5% charcoal-treated FCS, and the cells were left quiescent for 18 h. They
were challenged with the indicated amounts of the androgen R1881 (dis-
solved in ethanol) and control cells were treated with the vehicle alone.
Lysates were prepared as described previously (Migliaccio et al., 1998),
and protein concentrations were measured using a Bio-Rad protein assay
kit (Bio-Rad Laboratories). Cell lysates (2 mg/ml protein concentration)
were immunoprecipitated with either the mouse monoclonal anti-Src anti-
body (clone 327; Calbiochem) or the rabbit polyclonal anti-p85 antibody
(UBI) as reported previously (Migliaccio et al., 1998; Castoria et al., 2001).
Src kinase assay was performed as described in Migliaccio et al. (1996),
using acidified enolase as a substrate. For Rac assay, quiescent NIH3T3 fi-
broblasts at 70% confluence were maintained for 3 h in serum-free DME
and stimulated with the androgen R1881 (dissolved in ethanol) for the in-
dicated times. Control cells were treated with the vehicle alone (0.001%,
final concentration). Fresh lysates (4 mg/ml of protein concentration) were
prepared and incubated with the PAK-1 PBD agarose (UBI) as reported
previously (Benard et al., 1999). The eluted proteins were immunoblotted
for Rac detection.
Electrophoresis and immunoblotting
Electrophoresis and immunoblotting procedures were performed as de-
scribed in Migliaccio et al. (1998). Rac was detected with the mouse
monoclonal anti-Rac antibody (clone 23A8; UBI). The rabbit polyclonal
anti-AR antibodies (either C-19 or N-20; Santa Cruz) were used to reveal
AR. Src was detected with the mouse monoclonal anti-Src antibody (clone
327; Calbiochem) and p85 was immunoblotted using the rabbit polyclonal
anti-p85 antibody (UBI). ER  was immunoblotted using the rat monoclo-
nal anti-ER  (H222) antibody and ER  using the rabbit polyclonal anti-ER 
antibody (UBI). PgR was detected using mouse monoclonal anti-PgR anti-
body (StressGen Biotechnologies). Immunoreactive proteins were revealed
by the ECL detection system (Amersham Biosciences).
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